Evaluation of the efficacy of a live <i>Escherichia coli</i> biotherapeutic product (asymptomatic bacteriuria <i>E. coli</i> 212)
These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.
Authors
- Beatriz Martínez López (ORCID: https://orcid.org/0000-0003-1855-0097)
- Hilla Chen (ORCID: https://orcid.org/0000-0001-5549-9484)
- Jodi L. Westropp (ORCID: https://orcid.org/0000-0003-1287-3979)
- Jonathan D. Dear (ORCID: https://orcid.org/0000-0002-7166-1442)
- David J. Klumpp (ORCID: https://orcid.org/0000-0002-1237-8364)
- Gilad Segev (ORCID: https://orcid.org/0000-0003-4714-3159)
- Jully Pires (ORCID: https://orcid.org/0009-0007-5063-1045)
- Anthony J. Schaeffer (ORCID: https://orcid.org/0000-0002-5546-5118)
Institutions
- Northwestern University (US)
- Hebrew University of Jerusalem (IL)
- University of California, Davis (US)
Publication Details
- Journal
- Journal of Veterinary Internal Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/jvim.17167
- Primary Topic
- Urinary Tract Infections Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Morris Animal Foundation